Table 2 Comparison of biochemical and clinical parameters at baseline and after 3 months of treatment for the study groups.

From: Effect of trimetazidine on left ventricular functions and cardiac biomarkers in diabetic patients with left ventricular diastolic dysfunction: a randomized controlled trial

Variables

 

TMZ group (n = 30)

Placebo group (n = 29)

p-value

FBG (mg/dl)

Baseline

146 (124.7–217.25)

156 (126.5–189)

0.921a

After 3 months

150.5 (108- 203.5)

159 (112–195)

0.838a

% change

−2.22 (−21.87 −12.42)

0 (−22.44–19.12)

0.638a

HbA1c %

Baseline

7.44 ± 1.87

8.15 ± 1.94

0.157b

After 3 months

7.51 ± 1.59

7.8 ± 2.18

0.559b

% change

0 (−7.74–9.89)

−4.28 (−21.13-10.06)

0.115a

TC (mg/dl)

Baseline

184.51 ± 47.37

182.33 ± 45.42

0.859b

After 3 months

174.41 ± 30.51

193.35 ± 51.62

0.096b

% change

−1.43 ± 21.87

2.14 ± 27.56

0.583b

LDL-C (mg/dl)

Baseline

119.29 ± 45.05

115.1 ± 40.67

0.711b

After 3 months

103.43 ± 28.31

125.34 ± 45.27

0.032*b

% change

−4.72 ± 34.49

7.69 ± 39.69

0.204b

HDL-C (mg/dl)

Baseline

40.62 ± 8.65

40.68 ± 10.69

0.979b

After 3 months

43.89 ± 8.47

40.43 ± 8.58

0.979b

% change

11.92 ± 31.41

−0.63 ± 33.72

0.144b

TG (mg/dl)

Baseline

115 (96–153)

126.9 (87.5–148.5)

0.975a

After 3 months

128 (102.5- 153.5)

120 (95–169.75)

0.528a

% change

1.29 (−16.13 −30.08)

7.14 (−15.69 −33.01)

0.868a

TNF-α (ng/L)

Baseline

112.5 (67.54–143.87)

95.88 (57.73 −130.88)

0.332a

After 3 months

107.28 (72.52–168.61)

88.92 (63.08–100.31)

0.059a

% change

2.64 (−13.79–26.61)

27.89 (−22.12 −61.49)

0.739a

TGF-β1(ng/ml)

Baseline

6.32 (4.65–12.75)

6.61 (4.63–8.66)

0.808a

After 3 months

7.37 (5.19–12.24)

7.54 (5.66–9.22)

0.622a

% change

11.09 (−11.54–62.32)

27.89 (−22.12–61.49)

0.988a

Nt-proBNP (pg/ml)

Baseline

47.3 (31.76–73.24)

39.4 (30.63–63.31)

0.231a

After 3 months

60.31 (34.89–76.3)

57.28 (38.52–70.86)

0.802a

% change

9.71 (−6.22–39.73)

17.22 (−6.85 −83.14)

0.310a

mMRC dyspnea score

Baseline

1 (0–3)

1 (1–3)

0.055a

After 3 months

0 (0–1)

1 (0.5–3)

0.015*a

SBP (mm Hg)

Baseline

123.33 ± 12.67

130.38 ± 10.89

0.026*b

After 3 months

124.87 ± 15.5

131.03 ± 14.89

0.125b

% change

1.75 ± 12.38

0.68 ± 11.57

0.732b

DBP (mm Hg)

Baseline

76.33 ± 8.4

80.76 ± 7.72

0.04*b

After 3 months

77.33 ± 10.12

84.24 ± 11.98

0.02*b

% change

1.87 ± 13.16

4.31 ± 10.55

0.437b

  1. Data were presented as mean ± standard deviation or median (interquartile range); FBG: fasting blood glucose; HbA1c: glycated hemoglobin; TC: total cholesterol; LDL-C: low-density lipoprotein; HDL-C: high-density lipoprotein; TG: triglycerides; TNF-α: tumor necrosis factor alpha; TGF-β1: transforming growth factor beta 1; NT-proBNP; N- terminal pro brain natriuretic peptide; mMRC: modified Medical Research Council; SBP: systolic blood pressure; DBP: diastolic blood pressure.
  2. Statistical tests: a Mann-Whitney test, p-value ≥ 0.05; b Un-paired student t-test, p-value ≥ 0.05; * p-value < 0.05 is statistically significant.
Back to article page